| Investor | Prosight Management, LP |
13D/G Filings
This page shows a list of all the recent 13D/G filings made by Prosight Management, LP . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).
When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.
| Date | Form | Target | Prev Shares |
Current Shares |
Change (Percent) |
Ownership (Percent) |
Change (Percent) |
|
|---|---|---|---|---|---|---|---|---|
| 2026-02-13 | 13G/A | ADCT / ADC Therapeutics SA | 7,195,374 | 8,477,338 | ||||
| 2026-02-13 | 13G/A | MGTX / MeiraGTx Holdings plc | 4,356,571 | 3,211,788 | ||||
| 2026-02-06 | 13G | JANX / Janux Therapeutics, Inc. | 3,157,220 | |||||
| 2025-11-28 | 13G | OKUR / OnKure Therapeutics, Inc. | 745,649 | |||||
| 2025-11-13 | 13G/A | ADCT / ADC Therapeutics SA | 9,617,531 | 7,195,374 | ||||
| 2025-11-13 | 13G/A | MURA / Mural Oncology plc | 900,000 | 0 | ||||
| 2025-11-13 | 13G/A | STTK / Shattuck Labs, Inc. | 6,684,900 | 6,543,240 | ||||
| 2025-06-26 | 13G | MURA / Mural Oncology plc | 900,000 | |||||
| 2025-05-14 | 13G/A | MGTX / MeiraGTx Holdings plc | 4,052,714 | 4,356,571 | ||||
| 2025-02-12 | 13G/A | VINC / Vincerx Pharma, Inc. | 1,678,635 | 111,755 | ||||
| 2024-11-13 | 13G/A | ADCT / ADC Therapeutics SA | 6,471,800 | 9,617,531 | ||||
| 2024-11-13 | 13G/A | VINC / Vincerx Pharma, Inc. | 2,497,218 | 1,678,635 | ||||
| 2024-11-13 | 13G/A | ADCT / ADC Therapeutics SA | 6,471,800 | 9,627,017 | ||||
| 2024-11-13 | 13G/A | STTK / Shattuck Labs, Inc. | 5,370,000 | 6,684,900 | ||||
| 2024-08-16 | 13G/A | STTK / Shattuck Labs, Inc. | 2,782,797 | 5,370,000 | ||||
| 2024-05-03 | 13G | VINC / Vincerx Pharma, Inc. | 2,497,218 | |||||
| 2024-02-13 | 13G/A | MGTX / MeiraGTx Holdings plc | 4,080,804 | 4,052,714 | ||||
| 2024-02-13 | 13G/A | LBPH / Longboard Pharmaceuticals, Inc. | 948,012 | 0 | ||||
| 2024-02-13 | 13G/A | KZR / Kezar Life Sciences, Inc. | 4,073,229 | 3,365,333 | ||||
| 2024-02-13 | 13G/A | NSTGQ / NS Wind Down Co., Inc. | 3,150,000 | 0 | ||||
| 2024-02-13 | 13G/A | ADCT / ADC Therapeutics SA | 4,304,518 | 6,471,800 | ||||
| 2024-02-13 | 13G/A | ORIC / ORIC Pharmaceuticals, Inc. | 2,280,778 | 1,578,263 | ||||
| 2024-01-02 | 13G | STTK / Shattuck Labs, Inc. | 2,782,797 | 2,782,797 | ||||
| 2023-09-01 | 13G | NSTGQ / NS Wind Down Co., Inc. | 3,150,000 | |||||
| 2023-06-12 | 13G | ORIC / ORIC Pharmaceuticals, Inc. | 2,280,778 | |||||
| 2023-05-15 | 13G | MGTX / MeiraGTx Holdings plc | 4,080,804 | 4,080,804 | ||||
| 2023-04-21 | 13G | KZR / Kezar Life Sciences, Inc. | 4,073,229 | 4,073,229 | ||||
| 2023-04-20 | 13G | LBPH / Longboard Pharmaceuticals, Inc. | 948,012 | |||||
| 2023-04-17 | 13G | ADCT / ADC Therapeutics SA | 4,304,518 | 4,304,518 | ||||
| 2022-02-14 | 13G/A | XCUR / Exicure, Inc. | 4,984,265 | 2,503,704 | ||||
| 2021-08-20 | 13G | XCUR / Exicure, Inc. | 4,984,265 | |||||
| 2021-02-12 | 13G/A | ALDX / Aldeyra Therapeutics, Inc. | 1,784,033 | 908,488 | ||||
| 2020-02-25 | 13G | ALDX / Aldeyra Therapeutics, Inc. | 1,784,033 | |||||
| 2020-02-14 | 13G/A | TLGT / Teligent Inc | 3,547,607 | 1,484,527 | ||||
| 2019-02-14 | 13G/A | TLGT / Teligent Inc | 3,635,000 | 3,547,607 | ||||
| 2019-02-14 | 13G/A | TPST / Tempest Therapeutics, Inc. | 256,739 | |||||
| 2019-02-14 | 13G/A | CDTX / Cidara Therapeutics, Inc. | 1,647,879 | 245,764 | ||||
| 2019-02-14 | 13G/A | EIGR / Eiger BioPharmaceuticals, Inc. | 678,793 | 0 | ||||
| 2018-10-26 | 13G | TPST / Tempest Therapeutics, Inc. | 1,991,100 | |||||
| 2018-05-07 | 13G | TLGT / Teligent Inc | 3,635,000 | |||||
| 2018-02-13 | 13G/A | EIGR / Eiger BioPharmaceuticals, Inc. | 728,736 | 678,793 | ||||
| 2018-02-13 | 13G/A | CMRX / Chimerix, Inc. | 2,462,456 | 1,478,519 | ||||
| 2018-02-13 | 13G/A | CDTX / Cidara Therapeutics, Inc. | 873,630 | 1,647,879 | ||||
| 2017-11-09 | 13G | EIGR / Eiger BioPharmaceuticals, Inc. | 728,736 | |||||
| 2017-06-16 | 13G | CDTX / Cidara Therapeutics, Inc. | 873,630 | |||||
| 2017-01-30 | 13G | CMRX / Chimerix, Inc. | 2,462,456 | |||||
| 2016-02-12 | 13G/A | BSTG / Biostage Inc | 184,360 | |||||
| 2015-02-19 | 13G | BSTG / Biostage Inc | 788,900 |
